TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| S | %ret | 1 | 1 | 4 | 4 | 5 | -1 | -2 | 1 | 3 | 1 |
| S | %wins | 25 | 25 | 50 | 75 | 50 | 50 | 46 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12/9/10 18:39 | 12/8/10 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Flanagan Thomas James | CA | O | SVP,CIO | S | -40 | 53.37 | 33 | -1 | -2 | 42 | D | -8 | -5 | -1 | -1 | -7 | -1 | 0 | -1 | 1 | 4 | 7 | -3 | 10 | 10 |
1/29/09 17:19 | 1/29/09 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Flanagan Thomas James | CA | O | SVP,CIO | S | -191 | 54.71 | 33 | -3 | -8 | 38 | 0 | 4 | -11 | -7 | 15 | 6 | |||||||||
11/6/08 17:35 | 11/4/08 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Flanagan Thomas James | CA | O | SVP,CIO | S | -103 | 60.48 | 33 | -2 | -4 | 41 | D | -21 | 3 | 41 | -4 | -1 | 17 | 9 | -1 | 4 | -2 | 1 | 2 | -16 | -4 |
10/28/08 13:27 | 10/24/08 | AMGN | Amgen Inc | DE | Health | BioPrd | Biological Products, (No Diag | Flanagan Thomas James | CA | O | SVP,CIO | S | -300 | 57.72 | 33 | -5 | -12 | 38 | D | -27 | -4 | 30 | -12 | -17 | 6 | 8 | 10 | 9 | 12 | 0 | 0 | -7 | -1 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |